使用托伐普坦片你竟然不知道这些？

Heart failure (heart failure) is a serious and terminal stage of various heart diseases, which seriously affects the quality of life and life span of patients. With the acceleration of population aging, the increasing number of people with heart failure has become an important social public health issue. Tolvaptan tablets are a new type of selective arginine vasopressin (AVP) receptor antagonist. Since 2003, a number of clinical studies have been conducted to observe its role in the treatment of heart failure.

Tolvaptan tablets are a new type of non-peptide selective vasopressin V2 receptor antagonist, which is used to treat hypervolemic or isovolemic hyponatremia associated with heart failure, liver cirrhosis, and syndrome of inappropriate secretion of antidiuretic hormone. It is the only oral selective vasopressin V2 receptor antagonist approved for the treatment of this disease. The basic drugs for the treatment of heart failure are diuretics, angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists, beta-blockers and mineralocorticoid receptor antagonists. Diuretics are mostly aphrodisiacs, thiazide diuretics, etc., which increase the incidence of hyponatremia in patients. At the same time, the occurrence of diuretic resistance will also seriously affect the clinical efficacy of patients.

Severe electrolyte imbalance can lead to arrhythmia, aggravate heart failure, and affect its prognosis. Tolvaptan tablets can bind to V2 receptors on the collecting ducts and block their activity, thus blocking the reabsorption of renal water mediated by V2 receptors, reducing body fluid retention, reducing volume load, increasing sodium ion levels, helping excess water to be excreted from the urine, while having little effect on sodium and potassium, and helping to eliminate peripheral edema. China’s 2018 Guidelines for the Diagnosis and Treatment of Heart Failure recommend tolvaptan tablets for patients who are ineffective in conventional diuretic treatment, have hyponatremia, or are prone to renal damage, and are given a Class IIa recommendation.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.